Вы искали: rheumatoid (Голландский - Английский)

l04aa14 treatment of the signs and symptoms of rheumatoid arthritis
l04aa14 treatment of the signs and symptoms of rheumatoid

points to consider on clinical investigation of medicinal products for treatment of rheumatoid arthritis.
note for guidance on the clinical development of medicinal products for the treatment of hiv infection

clinical investigation of slow-acting anti-rheumatic medicinal products in rheumatoid arthritis
clinical investigation of slow-acting anti-rheumatic medicinal products in rheumatoid arthritis

een antilichaam genoemd “rheumatoid factor” kan worden gevonden in 80% van de patiënten.
an antibody called “rheumatoid factor” can be found in 80% of patients.

adjustment for multiplicity and related topics points to consider on biostatistical/methodological issues arising from cpmp discussion on licensing applications: adjustment for baseline covariates points to consider on clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for treatment of dyslipoproteinaemia points to consider on clinical investigation of slow-acting anti-rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti-fungal agents for invasive fungal infections points to consider on biostatistical/methodological issues arising from cpmp discussion on licensing applications:
adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow-acting anti-rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti-fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications: